Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX versus PBZ SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX versus PBZ SR.
CLARINEX vs PBZ-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. It inhibits histamine release from mast cells and reduces allergic inflammation.
Antihistamine; H1-receptor antagonist that competes with histamine for binding at H1 receptor sites, thereby preventing histamine-mediated allergic responses.
5 mg orally once daily.
100-200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 27 hours (range 20-30 hours). This long half-life supports once-daily dosing and allows for steady-state concentrations within 7 days.
Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function; clinically relevant dosing every 4-6 hours is recommended.
Desloratadine is primarily eliminated via renal excretion (~40% as metabolites) and fecal elimination (~45% as metabolites). Less than 2% is excreted unchanged in urine.
Primarily renal excretion (80-90% as unchanged drug) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 5-10%.
Category C
Category C
Antihistamine
Antihistamine